and 4-amino-4-deoxy-N10-methylpteroic acid, was confirmed in human urine samples and quantitated in patients' plasma by liquid chromatography, the respective maximum plasma concentrations being 250 (6) , and liver tissue in humans (9) .
Methotrexate triglutamate has been also reported in human erythrocytes and leukemic cells (6) , and 4-amino-4-deoxy-N'#{176}-methylpteroic acid is present as a metabolite in plasma and urine of patients receiving high doses of methotrexate (10) . Using HPLC, we quantitatively determined the metabolites after high-dose therapy with methotrexate.
We also investigated the influence of these metabolites on EIA and RIA. 
Materials and Methods

Materials
Determination of Methotrexate and Its Metabolites
The concentration of methotrexate in plasma was determined by EIA and RIA as described previously (11) . We separated components in the extract of plasma by HPLC, using the Glenco HPLC system (Glenco Scientific, Inc., Figure 1 shows the chromatograms for plasma samples before and 6 h after the start of the infusion. The latter clearly demonstrates the presence of 7-hydroxymethotrexate, methotrexate, and 4-amino-4-deoxy-N'#{176}-methylpteroic acid. Figure 2 shows Figure 2 suggest that, for the same plasma samples, HPLC is more specific than EIA for methotrexate, further confirming that both EIA and RIA are inferior for specifically quantitating methotrexate itself.
Discussion
In some early clinical trials with high-dose methotrexate and citrovorum-factor rescue, the fatality rate was 6% (15). Because of this severe toxicity, quantitation of drug in the blood became mandatory.
Our 
